CN101010078A - 作为药物的杂环化合物 - Google Patents

作为药物的杂环化合物 Download PDF

Info

Publication number
CN101010078A
CN101010078A CNA2005800272537A CN200580027253A CN101010078A CN 101010078 A CN101010078 A CN 101010078A CN A2005800272537 A CNA2005800272537 A CN A2005800272537A CN 200580027253 A CN200580027253 A CN 200580027253A CN 101010078 A CN101010078 A CN 101010078A
Authority
CN
China
Prior art keywords
replaces
optional
cycloalkyl
alkyl
heteroaryl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA2005800272537A
Other languages
English (en)
Chinese (zh)
Inventor
R·马丁
B·T·弗拉特
J·D·卡尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Exelixis Inc
Original Assignee
Exelixis Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Exelixis Inc filed Critical Exelixis Inc
Publication of CN101010078A publication Critical patent/CN101010078A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/54—Nitrogen and either oxygen or sulfur atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
CNA2005800272537A 2004-08-10 2005-08-09 作为药物的杂环化合物 Pending CN101010078A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US60023904P 2004-08-10 2004-08-10
US60/600,239 2004-08-10

Publications (1)

Publication Number Publication Date
CN101010078A true CN101010078A (zh) 2007-08-01

Family

ID=35908114

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA2005800272537A Pending CN101010078A (zh) 2004-08-10 2005-08-09 作为药物的杂环化合物

Country Status (9)

Country Link
US (1) US7902237B2 (https=)
EP (1) EP1776112A4 (https=)
JP (1) JP2008509912A (https=)
CN (1) CN101010078A (https=)
AU (1) AU2005272916A1 (https=)
BR (1) BRPI0514269A (https=)
CA (1) CA2574279A1 (https=)
MX (1) MX2007001539A (https=)
WO (1) WO2006020680A2 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111263635A (zh) * 2017-08-10 2020-06-09 德克萨斯农业及机械体系综合大学 Nr4a1配体、药物组合物以及相关使用方法

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090156644A1 (en) * 2005-07-21 2009-06-18 Jacob Westman Use of thiazole derivatives and analogues in the treatment of cancer
DE102007003524A1 (de) * 2007-01-19 2008-09-04 MEDICE Arzneimittel Pütter GmbH & Co. KG Arzneimittel zur Behandlung und/oder Prävention von Arteriosklerose
WO2008090356A1 (en) * 2007-01-25 2008-07-31 Betagenon Ab Thiazolidinone derivatives useful in the treatment of cancer and disorders caused by excess adiposity
CN101274918A (zh) * 2007-03-30 2008-10-01 中国科学院上海药物研究所 一类取代五元杂环化合物,其制备方法和医学用途
WO2010086613A1 (en) 2009-01-30 2010-08-05 Betagenon Ab Compounds useful as inhibitors as ampk
WO2012106581A1 (en) * 2011-02-03 2012-08-09 The University Of Chicago Fxr inhibitor, bile acid sequestrant as combination therapy for cholesterol reduction
NZ734451A (en) * 2012-06-19 2018-12-21 Intercept Pharmaceuticals Inc Preparation, uses and solid forms of obeticholic acid
JP6556129B2 (ja) 2013-08-01 2019-08-07 アメリカ合衆国 ファルネソイドｘ受容体の阻害剤及び医薬としての使用
SI3043865T1 (sl) 2013-09-11 2021-04-30 Institut National De La Sante Et De La Recherche Medicale (Inserm) Metode in farmacevtski sestavki za zdravljenje virusne okužbe s hepatitisom B
EP2952188A1 (en) * 2014-06-03 2015-12-09 Universität Bern Thiazolidinones as cellular anandamide uptake inhibitors and their use in the treatment of psychiatric or neurological disorders and inflammation, in particular neuroinflammation
EP3148541B1 (en) 2014-05-28 2020-09-02 Universität Bern Thiazolidinones as cellular anandamide uptake inhibitors and their use in the treatment of psychiatric or neurological disorders and inflammation, in particular neuroinflammation
EP3715348A1 (en) 2015-03-26 2020-09-30 Akarna Therapeutics, Ltd. Fused bicyclic compounds for the treatment of disease
TW201741307A (zh) * 2016-02-22 2017-12-01 艾洛斯生物製藥公司 Ｆｘｒ調節劑及其使用方法
WO2018178260A1 (en) 2017-03-30 2018-10-04 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for reducing persistence and expression of episomal viruses

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE523919A (https=) * 1952-10-31
US2719162A (en) * 1954-03-29 1955-09-27 Eastman Kodak Co 5-(3-hydroxybenzylidene)-3-phenyl-2-phenylimino-4-thiazolidone and process
US3097100A (en) * 1960-01-25 1963-07-09 Eastman Kodak Co Thiazolidones as light stabilizers for plastic compositions
BE608790A (fr) 1960-10-08 1962-04-03 Kalle Ag Matériel photosensible.
US3314794A (en) 1964-05-13 1967-04-18 Eastman Kodak Co Ultraviolet absorbers
FR1604530A (https=) * 1967-06-06 1971-11-29
US5198454A (en) * 1991-12-03 1993-03-30 Texas A&M University System Use of OB-104 to treat ocular inflammation
JPH06128234A (ja) 1992-10-19 1994-05-10 Fuji Photo Film Co Ltd 不斉炭素原子を有する化合物およびそれからなる非線形光学材料
JP3871354B2 (ja) * 1994-07-29 2007-01-24 株式会社フジモト・コーポレーション 新規な２−（ｎ−シアノイミノ）チアゾリジン−４−オン誘導体
US6353006B1 (en) * 1999-01-14 2002-03-05 Bayer Corporation Substituted 2-arylimino heterocycles and compositions containing them, for use as progesterone receptor binding agents
ES2367539T3 (es) * 2001-12-21 2011-11-04 X-Ceptor Therapeutics, Inc. Moduladores heterocíclicos de receptores nucleares.

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111263635A (zh) * 2017-08-10 2020-06-09 德克萨斯农业及机械体系综合大学 Nr4a1配体、药物组合物以及相关使用方法

Also Published As

Publication number Publication date
EP1776112A4 (en) 2009-11-25
WO2006020680A2 (en) 2006-02-23
BRPI0514269A (pt) 2008-06-10
US7902237B2 (en) 2011-03-08
US20080132519A1 (en) 2008-06-05
EP1776112A2 (en) 2007-04-25
CA2574279A1 (en) 2006-02-23
MX2007001539A (es) 2007-04-23
AU2005272916A1 (en) 2006-02-23
JP2008509912A (ja) 2008-04-03
WO2006020680A3 (en) 2006-12-28

Similar Documents

Publication Publication Date Title
CN101010078A (zh) 作为药物的杂环化合物
JP5420908B2 (ja) 医薬的薬剤としてのアゼピノインドール誘導体
CN102358741A (zh) 作为药物的氮杂*并吲哚衍生物
EP1572660B1 (en) Isoquinolinone derivatives and their use as therapeutic agents
US8466143B2 (en) Azepine derivatives as pharmaceutical agents
JP5082033B2 (ja) Ｌｘｒのモジュレーター
CN102186825A (zh) 芳基gpr120受体激动剂和其用途
EP1782832A1 (en) Remedy for diabetes
CN105566276B (zh) 作为dpp-4抑制剂的苯并六元环衍生物及其应用
ES2331299T3 (es) Compuestos de lactama y su uso medico.
CN103059014A (zh) 新型杂芳基氨基衍生物
KR20190112292A (ko) 자가 면역 질환을 치료하기 위한 ror-감마 조절 인자로서의 n-｛[2-(피페리딘-1-일)페닐](페닐)메틸｝-2-(3-옥소-3,4-디하이드로-2h-1,4-벤족사진-7-일)아세트아미드 유도체 및 관련 화합물
ES2395267T3 (es) Uso de derivados del ácido (-)-(3-halometilfenoxi)-(4-halofenil) acético para el tratamiento de la resistencia a la insulina, la diabetes de tipo 2 y la hiperuricemia
WO2004080943A1 (ja) シンナミルアルコール誘導体化合物およびその化合物を有効成分として含有する薬剤
CN111393372B (zh) 一种苯并咪唑衍生物及其制备方法和用途
CN105377815A (zh) 氨基吡啶衍生物或其药用可接受盐和包括相同活性成分的药物组合物
CN105308040B (zh) 1,3-二氨基环戊烷甲酰胺衍生物
WO2002102780A1 (en) Tetrahydroquinoline derivative compound and drug containing the compound as active ingredient
CN103044250B (zh) 羧酸衍生物类化合物及其制备方法和应用
GB2263636A (en) Substituted triazolinones, triazolinethiones, and triazolinimines as neurotensin antagonists
WO2004080947A1 (ja) イミノエーテル誘導体化合物およびその化合物を有効成分として含有する薬剤
US20030120073A1 (en) Alpha-ketocarboxylic acid based inhibitors of phosphoryl tyrosine phosphatases
RU2355686C2 (ru) Ингибиторы глутаминфруктозо-6-фосфатамидотрансферазы
WO2024120369A1 (zh) 一种蛋白降解靶向嵌合体化合物及其组合物和应用
CN107434789A (zh) 苯并三氮唑类衍生物、及其制法和药物组合物与用途

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Open date: 20070801